Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy.

Petherick KJ, Conway OJ, Mpamhanga C, Osborne SA, Kamal A, Saxty B, Ganley IG. · 2015

Read Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. by Petherick KJ, Conway OJ, Mpamhanga C, Osborne SA, Kamal A, Saxty B, Ganley IG. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4416842.txt.

Introduction

Katy Petherick and co-authors blocked autophagy by drugging its initiating enzyme, in the Journal of Biological Chemistry in 2015. Autophagy recycles cell contents through lysosomes and helps tumors survive stress and chemotherapy, making it a tempting drug target. Yet no specific small-molecule inhibitor existed; the common blocker acts late and broadly. The team targeted ULK1, the kinase that starts the process, with a selective inhibitor and measured both the birth and the maturation of autophagosomes, the recycling sacs.

Inhibiting ULK1 stopped autophagosome initiation and also blocked their maturation, showing the enzyme works at both ends of the pathway. Cells under mTOR-driven autophagy signals still could not proceed. A specific early blocker gives researchers a cleaner tool than late-stage drugs, and gives drug developers a validated point of attack for diseases where autophagy protects the wrong cells.

Catalog record

CREATORPetherick KJ, Conway OJ, Mpamhanga C, Osborne SA, Kamal A, Saxty B, Ganley IG.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4416842

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Pharmacological Inhibition of ULK1 Kinase Blocks Mammalian Target of Rapamycin (mTOR)-dependent Autophagy* By Katy J. Petherick, Owen J. L. Conway, Chido Mpamhanga, Simon A. Osborne, Ahmad Kamal, Barbara Saxty, Ian G. Ganley Published in: The Journal of Biological Chemistry DOI: 10.1074/jbc.C114.627778 ABSTRACT Background: Autophagy is an intracellular lysosomal degradation pathway implicated in many diseases, but there are currently no specific autophagy inhibitors. Results: Small molecule inhibition of ULK1, the upstream autophagy initiating kinase, blocks autophagosome initiation and maturation. Conclusion: ULK1 plays a role in autophagosome maturation as well as initiation. Significance: ULK1 can be targeted to block autophagy for disease therapy. INTRODUCTION Macroautophagy, called autophagy in this instance, is a membrane-driven process that traffics intracellular components to the lysosome for recycling (1). It is essentially a cell survival mechanism and is up-regulated under conditions of stress, allowing cells to supply building blocks and energy to maintain function during periods of starvation. Autophagy also eliminates impaired or foreign components that if left to persist could cause damage. Due to these functions, autophagy has been linked to many diseases from neurodegeneration to cancer (2). It is therefore an attractive therapeutic target, especially in cancer where it acts as a survival mechanism allowing the tumor to cope with an increased metabolic demand and damage caused by chemotherapeutics (3, 4). Hence, autophagy inhibition is thought to be a viable treatment approach. However, to date there are no specific small molecule autophagy inhibitors, and this has hampered validation of autophagy as a potential target in cancer. Hydroxychloroquine has entered clinical trials as an autophagy inhibitor (5–11), but it is far from specific given that it disrupts lysosomal function. The lysosome is the end point of autophagy as well as most other intracellular transport pathways including endocytosis. The most understood pathway of autophagy activation occurs upon inhibition of mTOR,2 either by amino acid withdrawal or by a direct pharmacological block. This leads to activation of the ULK1 protein kinase complex followed by the VPS34 lipid kinase complex (12–15). This in turn leads to the recruitment of a unique ubiquitin-like conjugation system resulting in the conjugation of LC3, and its family members, to the lipid phosphatidylethanolamine in the forming autophagosome, or phagophore. This lipidated form of LC3, termed LC3-II, is thought to drive elongation and cargo incorporation into the autophagosome (16). Thus there are many potential targets to inhibit autophagy. Kinase inhibitors have proved successful in the clinic, making ULK1 and VPS34 attractive candidates for inhibition. Studies about specific VPS34 inhibitors have recently been published, and these substances do indeed inhibit autophagy (17–19). However, VPS34 is also essential for sorting in the endocytic pathway, meaning that like hydroxychloroquine, VPS34 inhibition also affects endocytosis and lysosomal turnover in general. ULK1, on the other hand, is believed to be specific for autophagy, although other roles cannot be ruled out at this stage (20). We therefore set out to identify compounds that could inhibit ULK1 activity, not only to act as tool reagents to aid research but importantly to provide a proof-of-principle that targeting ULK1 could block autophagy. EXPERIMENTAL PROCEDURES Reagents and Antibodies MRT compounds were synthesized as described (21). AZD8055 was from Selleck Chemicals, and bafilomycin A1 was from Enzo Life Sciences. Rabbit anti-ULK1, anti-ATG5, and anti-ATG13 were from Sigma. Rabbit anti-phospho-Ser-757 ULK was from Cell Signaling Technology, and rabbit anti-phospho-Ser-318 ATG13 was from Abnova. Mouse anti α-tubulin was from Merck-Millipore. Mouse anti-LC3 for immunofluorescence was from MBL International, and sheep anti-LC3, used for immunoblotting, was generated by the Division of Signal Transduction Therapy, University of Dundee, from recombinant full-length human GST-LC3b and affinity-purified. Recombinant DNA Procedures were performed using standard protocols and mutagenesis was performed using QuikChange site-directed mutagenesis (Stratagene). Constructs are described and available on the MRC-PPU Reagents website. Cell Culture Immortalized wild-type mouse embryonic fibroblasts (MEFs) have been described previously (22). LKB1 MEFs were a kind gift from Tomi Mäkelä (University of Helsinki, Finland) and have been described previously (23). ULK1/2 double knock-out MEFs were a kind gift from Craig Thompson (Memorial Sloan-Kettering Cancer Center) and have been described previously (24). TBK1/IKKϵ knock-out and matched MEFs were a kind gift from Shizuo Akira (Osaka University, Japan) and have been described previously (25). MEFs and 293T cells were grown in DMEM, supplemented with 10% fetal bovine serum and penicillin/streptomycin, and cultured at 37 °C, 5% CO2. For induction of autophagy, cells were typically grown to 75% confluency, washed twice, and incubated in Earle's balanced salt solution (EBSS) for 1 h (or complete medium as a control) unless indicated. MRT67307 (10 μm), MRT68921 (1 μm), AZD8055 (1 μm), or bafilomycin A1 (50 nm) was included where indicated. Transfection and transduction were as described (15). Cell Lysis and Immunoprecipitation Cell lysis and immunoprecipitation were carried out as described (15). Immunoblots were quantified by densitometry, using ImageJ. Immunofluorescence Immunofluorescence was carried out as described (26). Slides were visualized on a Nikon TiS inverted microscope, and images were processed using NIS Elements (Nikon) and Adobe Photoshop. Live Cell Microscopy Cells were washed and incubated in phenol red-free medium and imaged on a Nikon TiE inverted microscope with an Okolab environmental chamber at 37 °C, 5% CO2. Images were obtained and processed using NIS Elements (Nikon). Kinase Assays Initial ULK1 kinase assays were performed with GST-ULK1, produced in Sf9 cells, which is described on the MRC-PPU Reagents website. For other experiments, recombinant GST-ULK1 (wild type, kinase-dead (K46I), and M92T and M92Q) was expressed in 293T cells, purified, and eluted from a glutathione-Sepharose column. Kinase assays were carried out in 50 mm Tris-HCl, pH 7.4, 10 mm magnesium acetate, 0.1 mm EGTA, and 0.1% β-mercaptoethanol, containing 30 μm cold ATP, and 0.5 μCi of [γ-32P]ATP for 5 min at 25 °C. Prior to ATP addition, reaction mixes were prewarmed to 25 °C for 5 min. Reactions were stopped by the addition of sample buffer, followed by SDS-PAGE, transfer to nitrocellulose, and analysis by autoradiography and immunoblot. For IC50 curve measurements, kinase assays were performed as described (27), using myelin basic protein (Sigma) as a substrate. Kinase profiling was as described (28), performed by the International Centre for Kinase Profiling. Statistical Analysis Experiments were carried out a minimum of three times, and error bars represent S.E. Significance in related samples was determined by paired student's t test. A p value of 0.05 or less was deemed significant. RESULTS AND DISCUSSION In vitro screening of known kinase inhibitors led to the discovery that the TBK1 inhibitor, MRT67307 (29), also targeted ULK1 and ULK2 with high potency (IC50 values of 45 and 38 nm, respectively, Fig. 1A). It is of no surprise that a compound would target both ULK1 and ULK2, given the high degree of similarity between the kinase domains; it is also desirable given the degree of redundancy observed in knock-out mouse models (20). To find more potent inhibitors, we re-analyzed a closely related series of analogues generated during the original TBK1 screen. This led to the discovery of MRT68921 as the most potent inhibitor of both ULK1 and ULK2, with greater than a 15-fold reduction in the IC50 for ULK1 (2.9 nm) and greater than a 30-fold reduction for ULK2 (1.1 nm) (Fig. 1A). To see whether in vitro activity of the compounds

Read the complete text